Supplementary Materials
Supplementary The 2-year randomized population includes patients randomized to placebo or teriflunomide 14 mg for 96 weeks relative to individual randomization dates and is extracted from the TOWER randomized population.
Supplementary Table 2.
Adverse events for patients in the safety and 2-year study safety population receiving placebo or teriflunomide 14 mg. The 2-year study safety population includes patients receiving placebo or teriflunomide 14 mg treated for 96 weeks relative to individual randomization dates and is extracted from the TOWER safety population. AE, adverse event; SAE, serious adverse event.
